Abstract
Hospitals in Japan have complete autonomy in deciding whether to admit COVID-19 patients, similar to that of the US. Taking this into account, we estimated the effect of admitting COVID-19 patients on hospital profits, using instrumental variable (IV) regression. Using IVs related to government intervention enabled us to not only estimate the effect of admitting COVID-19 patients among “swing hospitals,” where both options (to admit or to not admit COVID-19 patients) could potentially be realized but to also evaluate the effect of government intervention on such hospitals. Our empirical results revealed that monthly profits per bed decreased by approximately JPY 600,000 (≈ USD 6,000) among swing hospitals, which is 15 times the average monthly profits in 2019. This overwhelming financial damage indicates that it would be costly for swing hospitals to treat COVID-19 patients because of their low suitability for admitting such patients. Given the implications of our main results, we propose an alternative strategy to handling surges in patients with new infectious diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by HIAS (Hitotsubashi Institute for Advanced Study). We thank the Tokyo Metropolitan Government for generously providing data on hospitals in Tokyo.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approval is required for the manuscript under the standard of the ethical review board in Hitotsubashi University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Associate Professor at the Graduate School of Economics, Hitotsubashi University. 2-1, Naka, Kunitachi, Tokyo 186-8601, Japan. Email: reo.takaku{at}r.hit-u.ac.jp Tel.: +81-42-580-8599.
↵§ Associate Professor at the Graduate School of Economics, Hitotsubashi University. 2-1, Naka, Kunitachi, Tokyo 186-8601, Japan. Tel.: +81-42-580-8598. Fax: +81-42-580-8598.
* This research is supported by HIAS (Hitotsubashi Institute for Advanced Study). We thank the Tokyo Metropolitan Government for generously providing data on hospitals in Tokyo. Reo Takaku is an advisor for community health policy planning (Chiiki Iryo Kousou in Japanese) in the Tokyo Metropolitan Government but has no competing interest in this research. We thank Soichiro Ebata and Tomohisa Arai for outstanding research assistance. We also acknowledge many suggestions and helpful comments from the participants in seminars at University of Tokyo, Hitotsubashi University, and Musashi University. All errors are our own.
Declarations of interest: none.
Data Availability
The data are prohibited to share anyone.
